A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor

Journal of Surgical Research

Volumn 63, Issue 1, 1996, Pages 248-255

  Marvin, Michael R ^a   Libutti, Steven K ^a   Kayton, Mark ^a   Kao, Janet ^a   Hayward, Joanne ^b   Grikscheit, Tracy ^a   Fan, Yan ^a   Brett, Jerold ^a   Weinberg, A ^a   Nowygrod, Roman ^a   Logerfo, Paul ^a   Feind, Carl ^a   Hansen, Kristen S ^a   Schwarz, Margaret ^a   Stern, David ^a   Chabot, John ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; RECOMBINANT ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR VOLUME;

EID: 0029948526     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0256     Document Type: Conference Paper

References (37)

1. Old, L., Benacerraf, B., Clark, D., Carswell, E., and Stockert, E. Role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 21: 1281, 1961.
2. Carswell, E., Old, L., Kassel, R., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666, 1975.
3. Nawroth, P., Handley, D., Matsueda, G., De Waal, R., Gerlach, H., Blohm, D., and Stern, D. Tumor necrosis factor-induced intravascular fibrin formation in Meth A fibrosarcomas. J. Exp. Med. 168: 637, 1988.
4. Old, L. Tumor necrosis factor. Science 230: 630, 1986.
5. Clauss, M., Murray, C., Vianna, M., De Waal, R., Thurston, G., Nawroth, P., Gerlach, H., Gerlach, M., Bach, R., Familletti, P., and Stern, D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor. J. Biol. Chem. 265: 7078, 1990.
6. Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P., Pan, Y-C., Olander, J., Connolly, D., and Stern, D. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172: 1535, 1990.
7. Kao, J., Ryan, J., Grett, J., Chen, J., Shen, H., Fan, T-G., Godman, G., Familletti, P., Wang, F., Pan, Y-C., Stern, D., and Clauss, M. Endothelial monocyte-activating polypeptide II. J. Biol. Chem. 267: 20239, 1992.
8. Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S., Kayton, M., Grikscheit, T., Chabot, J., Nowygrod, R., Greenberg, S., Kuang, W-J., Leung, D., Hayward, J., Kisiel, W., Heath, M., Brett, J., and Stern, D. Characterization of a novel tumor-derived cytokine. J. Biol. Chem. 269: 25106, 1994.
9. Laemmli, U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680, 1970.
10. Towbin, H., Strachelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications. Proc. Natl. Acad. Sci. USA 76: 4350, 1979.
11. Johnson, D., Gautsch, J., Sportsman, J., and Elder, J. Improved technique utilizing nonfat milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal. Tech. 1: 3, 1984.
12. Kaye, J., Porcelli, S., Tite, J., Barry, J., and Janeway, C. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J. Exp. Med. 158: 836, 1983.
13. Granstein, R., Margolis, R., Mizel, S., and Sauder, D. In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin-1 in the mouse. J. Clin. Invest. 77: 1020, 1986.
14. Kao, J., Fan, Y-C., Haehnel, I., Brett, J., Greenberg, S., Clauss, M., Kayton, M., Houck, K., Kisiel, W., Burnier, J., and Stern, D. A peptide derived from the amino terminus of endothelialmonocyte activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J. Biol. Chem. 269: 9774, 1994.
15. Fidler, I. Selection of successive tumor lines for metastasis. Nature 242: 148, 1973.
16. Rasheed, S., Nelson-Rees, W., Toth, E., Arnstein, P., and Gardner, M. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33: 1027, 1974.
17. West, R. Handbook of Chemistry and Physics. Cleveland, OH: CRC Press, 1966.
18. Emeis, J., Lindeman, J., and Nieuwenhuizen, W. Immunoenzyme histochemical localization of fibrin degradation products in tissues. Am. J. Pathol. 103: 337, 1981.
19. Abbruzzese, J., Levin, B., Ajani, J., Faintuch, J., Saks, S., Patt, Y., Edwards, C., Ende, K., and Gutterman, J. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 49: 4057, 1989.
20. Beutler, B., and Cerami, A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 32: 584, 1986.
21. Lienard, D., Ewalenko, P., Delmotte, J., Renard, N., and Lejeune, F. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolated perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10: 52, 1992.
22. Fraker, D., and Alexander, H. Isolated limb perfusion with high dose TNF for extremity melanoma and sarcoma. Important Adv. Oncol. 179: 192, 1994.
23. Berendt, M., North, R., and Kirstein, D. The immunological basis of endotoxin-induced tumor regression: Requirement for T-cell-mediated immunity. J. Exp. Med. 148: 1550, 1978.
24. Murray, J., Clauss, M., Denekamp, J., and Stern, D. Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: A potential mechanism of flavone acetic acid action in tumour vasculature. Int. J. Cancer 49:254, 1991.
25. Freudenberg, N., Joh, K., Westphal, O., Mittermayer, C., Freudenberg, M., and Glanos, C. Haemmorhagic tumour necrosis following endotoxin administration. Virchows Arch. 403: 377, 1984.
26. Haranaka, K., Satomi, N., and Sakurai, A. Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumor in nude mice. Int. J. Cancer 34: 263, 1984.
27. Asher, A., Mule, J., Reichert, C., Shiloni, E., and Rosenberg, S. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138: 963, 1987.
28. Shwartzman, G. Phenomenon of Local Tissue Reactivity and Its Immunological, Pathological and Clinical Significance. New York: Harper & Row (Hoeber), 1937. Pp. 1-461.
29. Movat, H., Burrowes, C., Cybolsky, M., and Dinarello, C. Acute inflammation and a Shwartzman-like reaction induced by interleukin 1 and tumor necrosis factor. Am. J. Pathol. 129: 463, 1987.
30. Lloyd, K., Gordon, C., Thampoe, I., and DiBenedetto, C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 52(18): 4948, 1992.
31. Golumbek, P., Lazenby, A., Levitsky, H., Jaffee, E., Karasuyama, H., Baker, M., and Pardoll, D. Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science 254: 713, 1991.
32. Ashet, A., Mule, J., Kasid, A., Restifo, N., Salo, J., Reichert, C., Jaffe, R., Fendly, B., Kriegler, M., and Rosenberg, S. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Immunology 146: 3227, 1991.
33. Blankenstein, T., Quin, Z., Uberla, K., Muller, W., Rosen, H., Volk, H-D., and Diamantstein, T. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J. Exp. Med. 173: 1047, 1991.
34. Golumbek, P., Azhari, R., Jaffee, E., Levitsky, H., Lazenby, A., Leong, K., and Pardoll, D. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res. 53: 5841, 1993.
35. Smith, D., Kunkel, S., Burdick, M., Wilke, C., Orringer, M., Whyte, R., and Strieter, R. Production of interleukin 10 by human bronchogenic carcinoma. Am. J. Pathol. 145: 18, 1994.
36. Smith, D., Kunkel, S., Standiford, T., Chensue, S., Rolfe, M., Orringer, M., Whyte, R., Burdick, M., Danforth, J., Gilbert, A., and Strieter, R. Production of interleukin 1 receptor antagonist by human bronchogenic carcinoma. Am. J. Pathol. 143: 794, 1993.
37. Fleiss, J. The Design and Analysis of Clinical Experiments. New York: Wiley, 1986.